Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021286
Filing Date
2023-05-11
Accepted
2023-05-11 16:21:17
Documents
68
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vtyx-20230331.htm   iXBRL 10-Q 2876922
2 EX-10.1 vtyx-ex10_1.htm EX-10 52932
3 EX-31.1 vtyx-ex31_1.htm EX-31 22811
4 EX-31.2 vtyx-ex31_2.htm EX-31 22832
5 EX-32.1 vtyx-ex32_1.htm EX-32 13581
6 EX-32.2 vtyx-ex32_2.htm EX-32 13602
  Complete submission text file 0000950170-23-021286.txt   10221009

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vtyx-20230331_cal.xml EX-101.CAL 50492
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vtyx-20230331_def.xml EX-101.DEF 234415
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtyx-20230331_lab.xml EX-101.LAB 486944
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtyx-20230331_pre.xml EX-101.PRE 385845
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtyx-20230331.xsd EX-101.SCH 53719
62 EXTRACTED XBRL INSTANCE DOCUMENT vtyx-20230331_htm.xml XML 2055705
Mailing Address 662 ENCINITAS BLVD., STE. 250 ENCINITAS CA 92024
Business Address 662 ENCINITAS BLVD., STE. 250 ENCINITAS CA 92024 (858) 945-2393
Ventyx Biosciences, Inc. (Filer) CIK: 0001851194 (see all company filings)

EIN.: 832996852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40928 | Film No.: 23911381
SIC: 2834 Pharmaceutical Preparations